Email this article SOME FACTORS RELATED TO DISLIPIDEMIA IN CANCER PATIENTS IN THAI NGUYEN NATIONAL HOSPITAL
About this article
Received: 26/05/20 Revised: 08/07/20 Published: 10/07/20Authors
1. Nguyen Thi Hoa
, TNU - University of Medicine and Pharmacy2. Nguyen Thi Chi, Thai Nguyen National Hospital
Abstract
This study aims to analyze some factor related to dislipidemia in cancer patients in Thai Nguyen National Hospital. By a longitudinal study method of 266 cancer patients were treated at least 3 cycles of chemotherapy. The results show that prechemotherapy, after the 3rd cycle, the TC, TG and LDL-C levels were higher, HDL-C were lower than before chemotherapy, with statistically significant differences. After the 3rd cycle, the prevalence of dislipidemia such as the TC, TG and LDL-C in the breast cancers, in patients treated with cyclophosphamid, in patients treated with AC regimen were higher than in patients with colon cancer, in patients treated with 5FU, in patients treated with FOLFOX regimen, with respectively statistically significant differences. The results show that having a significant alterations of lipid profile levels in cancer patients after chemotherapy. The lipid profile levels changed differently by tumor types and chemotherapeutic agents and regimens.
Keywords
Full Text:
PDF (Tiếng Việt)References
[1]. WHO, “Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018,” 2018. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/30207593. [Accessed May 2020].
[2]. E. C. De Haas, and R. Altena, “Early development of the metabolic syndrome after chemotherapy for testicular cancer,” Annals of Oncology, vol. 24, pp. 749-755, 2013.
[3]. M. Sharma, J. Tuaine, and B. McLaren, “Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells,” 2016. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726544/. [Accessed May 2020].
[4]. L. Vehmanen et al., “Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids,” Br J Cancer, vol. 91, no. 3, pp. 476-481, 2006.
[5]. Ministry of Health, Guidelines for the diagnosis and treatment of cancer at Decision 3338/QĐ-BYT 9th, September, 2013.
[6]. R. H. Hamoode et al,“Alteration in serum lipid profile levels in Iraqi women with breast cancer before and after chemotherapy,” Asian J Pharm Clin Res, vol. 11, no. 5, pp. 230-232, 2018.
[7]. X. Li, Z. Liu, and Y. Wu, “Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy,” Lipids in Health and Disease, vol. 17, no. 91, pp. 1-6, 2018.
[8]. G. P. Stathopoulos, G. S. Stergiou, and D. N. Kostare, “Influence of 5-fluorouracil on serum lipids,” Acta Oncologica, vol. 34, no. 2, pp. 253-256, 1995.
[9]. T. C. Wang et al.,“Association between Pretreatment Serum High-density Lipoprotein Cholesterol and Treatment Outcomes in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy: Findings from a Randomised Trial,” Journal of Cancer 2019, vol. 10, no. 16, pp. 3618-3623, 2019.Refbacks
- There are currently no refbacks.